Compare Nuvalent Inc (NUVL) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs VNET Group Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while VNET Group Inc trades at $7.7 (market cap $2.19B). The key difference: Nuvalent Inc is far larger — about 4.5× VNET Group Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| NUVL | VNET | |
|---|---|---|
Market Cap | $9.81B | $2.19B |
Sector | Technology | Technology |
52-Week High | $123.96 | $14.03 |
52-Week Low | $72.16 | $7.34 |
Enterprise Value | $8.52B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
VNET trades at $7.675, up 3.86% today, but faces bearish technical signals with 15 sell indicators against 0 buys. The company reported a Q1 2026 net loss of $1.20 per share, missing estimates, while revenue reached $390.13 million. Despite negative profitability margins, analyst consensus remains 62.5% buy-rated, citing strategic investor entry and AI-driven data center demand as growth catalysts.
The outlook hinges on execution of its data center capacity pipeline to reverse losses. Risks include persistent negative earnings, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic given the 54% average price target upside, but profitability improvement is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
